25.52
-0.09 (-0.35%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Beam Therapeutics Inc. | Bullish | Bullish |
Stockmoo Score
|
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mwg Management Ltd. | 31 Mar 2024 | 2,346,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 213.48%) | Buy |
| Median | 74.50 (191.93%) | |
| Low | 69.00 (Stifel, 170.38%) | Buy |
| Average | 74.50 (191.93%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 24.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 11 Sep 2024 | 69.00 (170.38%) | Buy | 23.65 |
| HC Wainwright & Co. | 22 Aug 2024 | 80.00 (213.48%) | Buy | 24.52 |
| 23 Jul 2024 | 80.00 (213.48%) | Buy | 30.32 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Aug 2024 | Announcement | Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results |
| 15 Jul 2024 | Announcement | Beam Therapeutics Announces Transition of Chief Financial Officer |
| 26 Jun 2024 | Announcement | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) |
| 14 Jun 2024 | Announcement | Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |